Skip to main content
. 2024 Feb 15;38(4):720–728. doi: 10.1038/s41375-024-02166-1

Fig. 1. CONSORT diagram for testing (AALL0331/0232) and training (AALL0932/1131) therapeutic trials.

Fig. 1

B-ALL, B-Cell Acute Lymphoblastic Leukemia; BCR/ABL1, Philadelphia chromosome-positive ALL by BCR-ABL1 oncoprotein; MRD, minimal residual disease; Day 29, end-of-induction minimal residual disease; Day 8, induction day 8 minimal residual disease; CNS, central nervous system involvement; Bone marrow M1, <5% lymphoblasts (remission) Bone marrow M2, 5–25% lymphoblasts; Bone marrow M3, >25% lymphoblasts. Of note, day 8 PB MRD testing was not routinely measured for earlier trials (AALL0331/0232) until partway through accrual.